Dr. Low Wang serves as a Medical Safety Officer and leads safety oversight efforts at CPC Clinical Research. She also currently serves on the United States Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee. At CPC, Dr. Low Wang provides oversight of pharmacovigilance and medical monitoring services to ensure adherence to the clinical study protocol including clarification of inclusion/exclusion criteria, drug interactions, assessment of subject discontinuation, protocol deviations, and overall conduct of the study. With over 13 years of clinical experience, she provides expert guidance to the study team, investigators and clinical research coordinators.
Dr. Low Wang also serves as Associate Professor of Medicine at the University of Colorado Anschutz Medical Campus School of Medicine Department of Medicine in the Division of Endocrinology, Diabetes and Metabolism. Dr. Low Wang has a strong interest in the development and implementation of therapies for diabetes, insulin resistance (including obesity), and cardiovascular disease. She has a background in vascular cell biology – insulin action in the vascular wall / mechanisms of atherosclerosis in diabetes and insulin resistance, and hyperglycemia/diabetes in hospitalized patients. She has co-authored approximately 30 peer-reviewed manuscripts. She is a Fellow of the American College of Physicians and member of the Endocrine Society and the American Diabetes Association.
Dr. Low Wang previously served as a panel member of the Colorado Multiple Institutional Review Board (COMIRB). She directs the University of Colorado Hospital inpatient Glucose Management Team and is Associate Director for Fellowship and Education for the University of Colorado Endocrinology Division. For the Endocrine Society, she is a member of the Trainee and Career Development Core Committee and has previously served on the Research Affairs Core Committee Clinical Research Subcommittee and the Scientific and Educational Programs Core Committee.